Indian women are facing a critical threat as a WHO report reveals the potential loss of 1.5 million years to cervical cancer by 2025.With urgent calls for increased screening and vaccination efforts, the economic gain from HPV shots could be a game-changer in the fight against this deadly disease.
What is Cervical Cancer?
Cervical cancer develops in the cells of the cervix, the lower part of the uterus that connects to the vagina. The primary cause of cervical cancer is persistent infection with high-risk human papillomavirus (HPV) types, which are sexually transmitted. Over time, these infections can lead to the development of precancerous lesions and, if untreated, progress to invasive cancer.
Risk Factors for Cervical Cancer
Several factors can increase the risk of developing cervical cancer:
- HPV Infection: The most significant risk factor. Persistent infection with high-risk HPV types is necessary for the development of cervical cancer.
- Smoking: Tobacco use is linked to an increased risk of cervical cancer.
- Weak Immune System: Women with weakened immune systems, such as those with HIV, are at higher risk.
- Multiple Sexual Partners: Having multiple sexual partners increases the likelihood of HPV infection.
- Early Sexual Activity: Engaging in sexual activity at a young age increases the risk of HPV infection.
Prevention Strategies
Preventing cervical cancer involves several strategies, including:
- HPV Vaccination: Vaccines like Gardasil and Cervarix protect against the most common high-risk HPV types.
- Regular Screening: Pap smears and HPV tests help detect precancerous changes early.
- Safe Sexual Practices: Using condoms and limiting the number of sexual partners can reduce the risk of HPV infection.
- Quit Smoking: Avoiding tobacco use can lower the risk of cervical cancer.
Cervical Cancer by 2025:India Faces Looming Burden of 1.5 Million Years of Life at Risk
In a concerning report by the Indian Council of Medical Research (ICMR), it has been warned that India is on the brink of a significant burden of cervical cancer, with a projected loss of 1.5 million years of life by 2025. The study conducted by ICMR revealed that 223 life years were lost per 100,000 women in 2016, a number that is expected to soar if urgent action is not taken.
One of the key strategies to combat this alarming trend, as emphasized by the ICMR, is the immediate scaling up of both screening and vaccination efforts to curb the spread of the disease. Currently, only 2% of Indian women undergo screening for cervical cancer, a figure that the ICMR urges to increase to 70% to effectively tackle the issue.
Certain states in India, including Mizoram, Arunachal Pradesh, Karnataka, and Nagaland, bear a higher burden of cervical cancer cases, underscoring the need for targeted interventions in these regions. It is noteworthy that Indian women are most susceptible to cervical cancer between the ages of 50 and 74, highlighting the importance of age-appropriate prevention and screening measures.
The World Health Organization (WHO) has set ambitious goals for the elimination of cervical cancer, which include achieving 90% vaccination coverage, 70% screening rates, and ensuring 90% treatment of cervical disease. Administering the Human Papillomavirus (HPV) vaccine to girls aged 9-14 is deemed crucial for prevention efforts, with a focus on early intervention to reduce the prevalence of the disease.
Furthermore, women living with HIV are identified as a particularly vulnerable group requiring special attention in prevention initiatives. The WHO report has underlined the potential economic benefits for India, estimating a 16-times economic gain by introducing the HPV vaccine for adolescent girls.
Despite the recommendations by the National Technical Advisory Group for Immunisation to include the HPV vaccine in the universal programme over five years ago, implementation has been delayed due to funding constraints. Cost-benefit analyses suggest that the government would need to invest $1.1 billion in the vaccine, with projected economic benefits outweighing the costs by 16.7 times.
On a positive note, the availability of a third made-in-India HPV vaccine signals progress in the fight against cervical cancer, with plans for a phased launch in all states in 2022. This development presents a significant opportunity to ramp up vaccination efforts and work towards reducing the burden of cervical cancer in India.
Economic Benefits of HPV Vaccination
The WHO report also emphasizes the economic gains from widespread HPV vaccination. By preventing cervical cancer, countries can save on treatment costs and improve productivity by reducing the number of women who lose their lives or are incapacitated by the disease. Investing in HPV vaccination programs can lead to significant long-term savings and better health outcomes.
Conclusion
Cervical cancer is a preventable disease that continues to pose a significant threat to women’s health, particularly in India. With increased awareness, regular screening, and widespread HPV vaccination, we can drastically reduce the incidence of cervical cancer and save millions of lives. As the WHO report highlights, the economic benefits of HPV vaccination are substantial, making it a wise investment for the future. Let us come together to support these initiatives and create a healthier world for all women.
As the country stands at a critical juncture in addressing the growing threat of cervical cancer, concerted efforts and investments in prevention, screening, and vaccination are imperative to safeguard the health and well-being of women across India.
Read also :National Watermelon Day 2024: Discover the Date, History, Significance, and 24 Amazing Facts
Read also :Cloves Syndrome Awareness Day 2024:Date, History, 15 Interesting Facts,Symptoms and Diagnosis
Read also :Teej 2024: Key Details,Date, Rituals, Puja, and why it is Celebrated Explained
